Press release
Schizophrenia Market Size 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Treatment Market, Statistics, and Companies by DelveInsight | Novartis, Zhejiang Jingxin Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Neurocrine Biosciences, Spinogenix, Cerevel
(Albany, USA) DelveInsight's "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of Schizophrenia, including historical and forecasted epidemiology, as well as Schizophrenia market trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.The Schizophrenia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Schizophrenia market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Schizophrenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Schizophrenia market.
Discover which therapies are expected to grab the Schizophrenia Market Share @ Schizophrenia Market Outlook- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Schizophrenia Market Report
• In July 2025, EuMentis Therapeutics, Inc., ("EuMentis"), a clinical-stage drug development company focused on advancing novel treatments for schizophrenia and other central nervous system (CNS) conditions, today announced that the U.S. Food and Drug Administration (FDA) has authorized its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of EM-221, the company's investigational phosphodiesterase 10A (PDE10A) inhibitor, in patients with schizophrenia.
• In May 2025, Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of data from the Phase 2 study of NBI-1117568 in adults with schizophrenia, which showed a significant improvement in symptoms and overall severity and highlighted new data on the safety and tolerability of the treatment. NBI-1117568 is the first and only investigational oral muscarinic M4 selective orthosteric agonist in clinical development as a potential treatment for schizophrenia. These results were shared as an oral presentation and poster at the American Society of Clinical Psychopharmacology 2025 Annual Meeting in Scottsdale, Arizona.
• In March 2025:- Boehringer Ingelheim conducted a study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term.
• In March 2025:- Teva Branded Pharmaceutical Products R&D, Inc. announced a study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia.
• In the 7MM, the total Schizophrenia prevalence cases were estimated to be approximately 6,029,994 in 2022, of which the US accounted for around 45.05%, while EU4 and the UK accounted for nearly 37.36%, and Japan accounted for approximately 17.59% of the total prevalent cases.
• Among the 7MM, the US accounted for nearly 37.20% of the total Schizophrenia diagnosed prevalent cases with nearly 1,412,470 cases in 2022. These cases are expected to increase during the study period (2020-2034).
• As per DelveInsight analysis, EU4 and the UK accounted for around 1,588,816 Schizophrenia diagnosed prevalent cases in 2022. These cases are expected to change during the study period (2020-2034)
• Among the EU4 and the UK, Germany accounted for the highest Schizophrenia prevalence cases representing nearly 28.50% of the cases, followed by the UK, and France, while Spain had the least cases in 2022
• According to estimates based on DelveInsight's epidemiology model, Schizophrenia exhibits a higher male preponderance than females in the US. Of the total diagnosed prevalent cases in the US, nearly 53.63% were males and 46.37% were females, in 2022.
• In the US, when the Schizophrenia diagnosed prevalent cases were segmented based on severity, the mild group accounted for nearly 567,336 cases, in 2022. As per the analysis, these cases are expected to increase, and the moderate group contributed around 37.03% of the diagnosed prevalent cases, while the severe group contributed a minimum of 22.81% respectively in 2022.
• In 2022, among the 7MM, Japan had the second highest cases of Schizophrenia, contributing approximately 17.59% to the total prevalent cases of Schizophrenia.
• The leading Schizophrenia Companies such as Novartis Pharmaceuticals, Zhejiang Jingxin Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., Neurocrine Biosciences, Spinogenix, Cerevel Therapeutics, LLC, LB Pharmaceuticals Inc., Merck Sharp & Dohme LLC, and others.
• Promising Schizophrenia Pipeline Therapies such as AQW051, JX11502MA, HS-10380, NBI-1117568, SPG302, CVL-231, LB-102, MK0557, and Luvadaxistat, and others.
Stay ahead in the Schizophrenia Therapeutics Market with DelveInsight's Strategic Report @ Schizophrenia Market Outlook- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Schizophrenia Epidemiology Segmentation in the 7MM
• Total Schizophrenia Prevalent Cases
• Total Schizophrenia Diagnosed Cases
• Schizophrenia Gender-specific Cases
• Schizophrenia Severity-specific Cases
• Schizophrenia Age-specific Treated Cases
• Total Schizophrenia Treated Cases
Download the report to understand which factors are driving Schizophrenia Epidemiology trends @ Schizophrenia Prevalence- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Schizophrenia Marketed Drugs
• ABILIFY MAINTENA (aripiprazole): Otsuka Pharmaceutical/Lundbeck
ABILIFY MAINTENA (aripiprazole) for extended-release injectable suspension, an IM depot formulation of aripiprazole, is a sterile lyophilized powder that, when reconstituted with sterile water for injection, forms an injectable suspension that can be administered monthly. ABILIFY MAINTENA is an atypical antipsychotic drugs market. The mechanism of action of aripiprazole in the treatment of schizophrenia and bipolar I disorder is unknown. The efficacy of aripiprazole could be mediated through a combination of partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at 5-HT2A receptors.
• UZEDY (risperidone): Teva Pharmaceuticals/MedinCell
UZEDY (risperidone) extended-release injectable suspension is indicated for the treatment of schizophrenia in adults. UZEDY administers risperidone through copolymer technology under license from MedinCell that allows for absorption and sustained release in the first subcutaneous injection. UZEDY is the only long-acting, subcutaneous formulation of risperidone available in both one- and two-month dosing intervals.
Schizophrenia Emerging Drugs
• Ulotaront (SEP-363856): Sumitomo Pharma/Otsuka Pharmaceuticals
Ulotaront (SEP-363856) is a trace amine-associated receptor 1 (TAAR1) agonist with serotonin 5-HT1A agonist activity, jointly developed by Sunovion Pharma and PsychoGenics, which is a small-molecule oral agent that does not bind to dopamine D2 or serotonin 5-HT2A receptors. Sunovion discovered Ulotaront in collaboration with PsychoGenics using it is in vivo phenotypic SmartCube platform and associated artificial intelligence algorithms.
• Brilaroxazine (RP-5063): Reviva Pharmaceuticals
Brilaroxazine (RP5063) is a new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia and other psychiatric disorders. RP5063 is a multimodal modulator of the serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT7 receptors and D2, D3, and D4 dopamine receptors in clinical development for multiple neuropsychiatric indications, including schizophrenia.
To learn more about Schizophrenia treatment guidelines, visit @ Schizophrenia Treatment Market Landscape- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Schizophrenia Drugs Market Insights
Schizophrenia treatment typically involves a combination of medication and psychosocial interventions aimed at managing the condition effectively. Pharmacotherapy plays a pivotal role in addressing schizophrenia symptoms, with a wide array of mono and combination pharmacological options available. Antipsychotic medications, categorized into first-generation (FGAs) and second-generation (SGAs), are commonly prescribed as first-line treatments. Some treatment approaches may involve a combination of antipsychotics and antiepileptic medications, tailored to specific patient groups. Both oral antipsychotics (OAP) and long-acting injectable therapies (LAI) are accessible options within each generation of antipsychotics drugs market. In clinical practice, a blend of both FGAs and SGAs is often utilized to effectively manage schizophrenia symptoms.
Schizophrenia Market Outlook
Schizophrenia is a severe and chronic mental disorder characterized by distorted thinking, perception, emotions, language, sense of self, and behavior. Its impact extends beyond patients to family members, caregivers, and society due to its lifelong nature and the likelihood of relapses. The disorder progresses through stages, including prodromal, active, and residual, each marked by specific symptoms such as hallucinations, suspiciousness, delusions, depression, withdrawal, anxiety, and difficulty concentrating. The treatment options for schizophrenia include antipsychotics medicine market, psychological counseling and social support, cognitive behavioral therapy, and electroconvulsive therapy (ECT).
Learn more about the FDA-approved drugs for Schizophrenia @ Drugs for Schizophrenia Treatment- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Schizophrenia Market Report:
• Study Period: 2020-2034
• Coverage: 7MM
• Schizophrenia Companies: Novartis Pharmaceuticals, Zhejiang Jingxin Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., Neurocrine Biosciences, Spinogenix, Cerevel Therapeutics, LLC, LB Pharmaceuticals Inc., Merck Sharp & Dohme LLC, and others.
• Schizophrenia Therapies: AQW051, JX11502MA, HS-10380, NBI-1117568, SPG302, CVL-231, LB-102, MK0557, and Luvadaxistat, among others.
• Schizophrenia Therapeutic Assessment: Schizophrenia currently marketed, and Schizophrenia emerging therapies
• Schizophrenia Market Dynamics: Schizophrenia market drivers and Schizophrenia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Schizophrenia Unmet Needs, KOL's views, Analyst's views, Schizophrenia Market Access and Reimbursement
Discover more about Schizophrenia Drugs in development @ Schizophrenia Clinical Trials Assessment- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Contents:
1. Schizophrenia Market Report Introduction
2. Executive Summary for Schizophrenia
3. SWOT analysis of Schizophrenia
4. Schizophrenia Patient Share (%) Overview at a Glance
5. Schizophrenia Market Overview at a Glance
6. Schizophrenia Disease Background and Overview
7. Schizophrenia Epidemiology and Patient Population
8. Country-Specific Patient Population of Schizophrenia
9. Schizophrenia Current Treatment and Medical Practices
10. Schizophrenia Unmet Needs
11. Schizophrenia Emerging Therapies
12. Schizophrenia Market Outlook
13. Country-Wise Schizophrenia Market Analysis (2020-2034)
14. Schizophrenia Market Access and Reimbursement of Therapies
15. Schizophrenia Market Drivers
16. Schizophrenia Market Barriers
17. Schizophrenia Appendix
18. Schizophrenia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Schizophrenia Market Size 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Treatment Market, Statistics, and Companies by DelveInsight | Novartis, Zhejiang Jingxin Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Neurocrine Biosciences, Spinogenix, Cerevel here
News-ID: 4127264 • Views: …
More Releases from DelveInsight Business Research

Low Grade Glioma Market Predicted to See Upsurge Through 2034, Highlights DelveI …
DelveInsight's "Low Grade Glioma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Low Grade Glioma, historical and forecasted epidemiology as well as the Low Grade Glioma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Low Grade Glioma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Low Grade Glioma…

Bladder Cancer Market to Show Remarkable Growth Trends from 2024 to 2034, DelveI …
DelveInsight's "Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bladder Cancer, historical and forecasted epidemiology as well as the Bladder Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Bladder Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bladder Cancer Market Forecast
https://www.delveinsight.com/sample-request/bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…

Paroxysmal Nocturnal Hemoglobinuria Market Expected to Experience Major Growth b …
DelveInsight's "Paroxysmal Nocturnal Hemoglobinuria Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Paroxysmal Nocturnal Hemoglobinuria, historical and forecasted epidemiology as well as the Paroxysmal Nocturnal Hemoglobinuria market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Paroxysmal Nocturnal Hemoglobinuria market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Paroxysmal Nocturnal Hemoglobinuria…

Pediatric Brain Tumors Market Set to Grow Substantially Through 2034, DelveInsig …
The Pediatric Brain Tumors market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pediatric Brain Tumors pipeline products will significantly revolutionize the Pediatric Brain Tumors market dynamics.
DelveInsight's "Pediatric Brain Tumors Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pediatric Brain Tumors, historical and forecasted epidemiology as well as the Pediatric Brain…
More Releases for Schizophrenia
Rising Mental Illness Burden Fuels Growth In The Schizophrenia Market: Pivotal F …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
Schizophrenia Market Size Growth Forecast: What to Expect by 2025?
In the past few years, the schizophrenia market size has seen robust growth. The projected growth from $5.82 billion in 2024 to $6.11 billion in 2025, signifies a compound annual growth rate (CAGR) of 5.0%. Factors such as increased…
Clozapine Market: Transforming the Treatment Landscape for Schizophrenia
Clozapine, an atypical antipsychotic medication, has emerged as a critical treatment option for patients with treatment-resistant schizophrenia and other severe psychiatric disorders. As one of the most effective therapies available for reducing symptoms in individuals who do not respond adequately to other antipsychotic medications, clozapine plays a vital role in modern psychiatry. This article provides a comprehensive overview of the clozapine market, exploring market information, key trends, challenges, and detailed…
Schizophrenia Drugs Market Opportunity | Size | Research Report
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: Schizophrenia Drugs Market was valued at USD 5.3 Billion in 2018 and is projected to reach USD 8.42 Billion by 2026, growing at a CAGR of 3.66% from 2019 to 2026.
Market Overview for Schizophrenia Drugs Market
Schizophrenia Drugs Market OverviewThe schizophrenia drugs market is experiencing significant growth driven by advancements in pharmacotherapy and increasing awareness about mental health disorders. Schizophrenia, a chronic and severe mental disorder affecting millions…
Schizophrenia Drugs Market - Restoring Balance, Inspiring Hope: Schizophrenia Dr …
Newark, New Castle, USA: The "Schizophrenia Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Schizophrenia Drugs Market: https://www.growthplusreports.com/report/schizophrenia-drugs-market/7871
This latest report researches the industry structure, sales, revenue,…
Schizophrenia Drugs Market - Leading the Way in Schizophrenia Treatment: Nurturi …
Newark, New Castle, USA - new report, titled Schizophrenia Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Schizophrenia Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Schizophrenia Drugs market. The report offers an overview of the market, which…
Schizophrenia Drug Market & Pipeline Insight
Schizophrenia is defined as a disorder of the brain which impacts the way in which a person acts, thinks, and sees the world. It has been observed that the patients suffering from schizophrenia generally tend to have an altered perception of reality, which reveals a significant diversion from the reality. In most cases, schizophrenia is diagnosed among people in the late teens or early adulthood. However, middle-aged people also could…